et al.. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
Introduction
Multiple myeloma (MM) is a universally fatal neoplasia characterized by the accumulation of malignant plasma cells (MMC) in the BM 1 . There is increasing evidence for a major role of interactions between MMC and BM stroma for the support of survival and proliferation of the MMC 2 .
Patients with MM can be grouped in accordance to cytogenetic aberrations identified by conventional metaphase cytogenetics or (interphase) fluorescence in situ hybridization (iFISH) in MMC 3, 4 . Patients can also be grouped in accordance to gene expression profiling (GEP) with a link between cytogenetic and GEP data 4, 5 . A good example is the correlation between the translocation t(4;14) and the overexpression of the multiple myeloma set domain (MMSET), or between the translocation t (11;14) and a high CCND1 overexpression 6, 7 . GEP has the potential to identify new pathways involved in the biology of MMC, in particular regarding the communication with the tumor environment [8] [9] [10] . DNA arrays permitted to show that some HMCLs expressed a gene coding for heparin binding epidermal growth factor-like growth factor (HB-EGF), a member of the epidermal growth factor family able to bind syndecan-1 11 . Further studies demonstrated that HB-EGF is a potent myeloma cell growth factor 12, 13 . Using Affymetrix microarrays, we also found that TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) and BCMA (B-cell maturation antigen), each gene coding for a receptor of B-cell activating factor (BAFF) 14, 15 and A Proliferation-Inducing Ligand (APRIL) [16] [17] [18] were overexpressed in malignant plasma cells compared to their normal counterparts 8,9 . BAFF is a tumor necrosis factor (TNF)-family member involved in the survival of normal and malignant B cells as well as normal plasmablasts 18, 19 . APRIL is highly expressed in several tumor tissues and stimulates the growth of tumor cells 16 . A third receptor specific for BAFF, BAFF-receptor (BAFF-R) was also identified 20 . We and others showed that BAFF and APRIL serum levels are elevated in patients with MM and that BAFF and APRIL contribute to the survival of some HMCLs and of primary MMC 21, 22 .
In this study, we have shown that the tumor environment is the main source of BAFF and APRIL in patients with MM and that TACI expression yields a functional receptor.
Using Affymetrix microarrays, we demonstrated that TACI high MMC displayed a mature plasma cell gene signature, indicating dependence on the BM environment.
In contrast, the TACI low group had a gene signature of plasmablasts suggesting an attenuated dependence on interactions with cells in the BM environment.
Materials and methods

Cell samples
XG-1, XG-3, XG-4, XG-5, XG-6, XG-7, XG-10, XG-11, XG-12, XG-13, XG-16, XG-19, and XG-20 human myeloma cell lines (HMCLs) were obtained as described 23 .
SKMM, OPM2, LP1 and RPMI8226 HMCLs were purchased from ATTC (LGC Promochem, France). MMC were purified from a first series of 65 myeloma patients at diagnosis (median age, 59 years) and a second series of 40 newly-diagnosed patients after written informed consent was given. In the first series, according to Durie-Salmon classification, 12 patients were of stage IA, 12 of stage IIA, 38 Jose, CA). CD3 + , CD14 + and CD15 + cells were sorted with a FACSAria cell sorter (Becton Dickinson). Memory B cells, polyclonal plasmablasts (PPCs), immature dendritic cells (DCs) and BM stromal cell lines (BMSCs) were generated as described previously 9, 24, 25 . BMSC culture supernatants were prepared from 3-day culture before reaching confluence and were stored at -20°c until use.
Osteoclasts
Peripheral blood mononuclear cells were obtained from 7 patients with MM after informed consent. Cells were cultured at 2.5 x 10 6 cells/ml in MEM-10% FCS. After 12 hours of culture, non-adherent cells were eliminated and adherent cells were cultured in MEM-10% FCS, RANKL (50 ng/ml, PeproTech, EC Ldt, London, UK), M-CSF (25 ng/ml, Peprotech), and 10 nM dexamethasone for 14 days. Before use, osteoslasts were phenotyped by RT-PCR (TRAP and cathepsin K expression), by cytometry (integrin v3 expression) and bone resorbing activity (OsteoLyse assay kit, Cambrex, Emerainville, France). Culture supernatants were prepared from mature osteoclasts cultured for 3 days with M-CSF, RANKL and DEX and were frozen at -20°C until use.
BAFF or APRIL ELISA
The concentration of BAFF was assayed using the ELISA as described previously 21 , and APRIL with an ELISA purchased from Bender MedSystems (Burlingame, CA) in accordance with the manufacturer's instructions.
Modulation of the gene expression profile by addition or deprivation of BAFF/APRIL in MMC
The modulation of gene expression by addition of BAFF and APRIL was investigated with the XG-13 HMCL 21 . XG-13 cells were starved of IL-6 for 2 hours, washed and cultured for 12 hours in RPMI1640/10% FCS. Then BAFF and APRIL (200 ng/mL each) were added in one culture group for 10 hours. We also investigated the modulation of gene expression profile in primary MMC by BAFF and APRIL. 26 . BM cells of a newly-diagnosed patient with TACI high MMC were harvested and whole BM cells (5 x 10 5 cells/mL) were cultured for 24 hours in RPMI1640-10%FCS. Then, 20 g/ml of TACI-Fc (R&D Systems, Abington, United Kingdom) were added for 10 hours in one culture group. Cells were harvested, labeled with CD138 MACS microbeads at 4°C and primary MMC were purified. RNA were extracted for gene expression profiling.
Preparation of complementary RNA (cRNA) and microarray hybridization
RNA was extracted using the RNeasy Kit (Quiagen, Hilden, Germany). Biotinylated cRNA was amplified with a double in-vitro transcription and hybridized to the human HG U133 A and B or U133 2:0 plus GeneChips, according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). Fluorescence intensities were quantified and analyzed using the GECOS software (Affymetrix).
Conventional and real-time RT-PCR
BCMA, TACI and BAFF-R PCR analysis was done as previously described 21 
Binding of BAFF to MMC
The binding of BAFF to HMCLs and primary MMC was determined using a human BAFF-murine CD8 biotinylated fusion protein (Ancell, Bayport, MN) and FACS analysis as previously described 21 .
Fluorescence in-situ hybridization (FISH)
Interphase FISH was performed according to our previously reported standard protocol 27 . Metaphase spreads and interphase cells were evaluated using a DM RXA2 fluorescence microscope (Leica, Bensheim, Germany).
Statistical analysis and TACI low and TACI high group definition
Gene expression data were normalized with the MAS5 algorithm and analyzed with our bioinformatics platform (RAGE, Remote Analysis of microarray Gene Expression) designed by Dr T Reme (INSERM U475, Montpellier, France). Hierarchical clustering was performed with the Cluster and Treeview softwares from Eisen 28 . We performed a two-sided supervised clustering between a group of patients with a high (TACI high ) and one with low (TACI low ) expression of TACI. To account for the log-normal distribution of TACI expression, we performed this analysis with decreasing proportions of patients in the TACI high and TACI low group: 40%, 25%, and 15%, respectively, of patients with the highest vs. lowest TACI expression. Genes were interpreted as differentially expressed if the p-value (Mann-Whitney test) was ≤ .01 and the ratio ≥ 1.5 or ≤ 0.67. A permutation test 29 was performed to generate 100 times two arbitrary groups comprising 40%, 25% or 15%, respectively, of patients in order to get an evaluation for the number of genes differentially expressed between two arbitrary groups (P ≤ .01 and ratio ≥ 1.5 or ≤ 0.67) by chance. Statistical comparisons were done with Mann-Whitney, Chi-square, or Student t-tests. In order to identify the cell type expressing BAFF or APRIL in the MM environment, BM CD3, CD14 and CD15 cells of 3 patients were purified. BAFF was mainly expressed by BM CD14 and CD15 cells and APRIL by CD14 cells. CD3 cells expressed BAFF and APRIL only at a low level ( Figure 1B ). To assess a broad range of populations present in the bone microenvironment, BMSCs and osteoclasts were also studied. BMSCs from 7 patients with MM expressed weakly BAFF and APRIL ( Figure 1C ). Of major interest, osteoclasts largely expressed APRIL gene. Median APRIL expression was 80-fold higher than that in BM environment (P = .001).
Results
BAFF
Osteoclasts also express BAFF gene but in the same extent as the BM environment.
BAFF and APRIL production by BM cells
The production of BAFF and APRIL was investigated in 3-day culture supernatants of BM cells of 10 newly-diagnosed patients, of 7 osteoclasts, and of 7 BMSCs. In agreement with real time RT-PCR data, low amount of BAFF and no APRIL could be found in BMSC supernatants. Median concentrations of 12.5 ng/ml of BAFF and 24.6 ng/mL of APRIL were measured in supernatants of BM cells. Again, in agreement with RT-PCR data, osteoclasts produced large amounts of APRIL (a concentration of 206 ng/ml), i.e. 8-fold higher than BM cells (P ≤ .001). The median production of BAFF by osteoclasts was 3-fold higher than that of BM cells (P ≤ .001).
TACI gene expression yields a functional BAFF-binding receptor in HMCLs and primary MMC.
Gene expression profiling (GEP) was performed on 17 HMCL using Affymetrix U133 A+B microarrays. On these, no probeset for BAFF-R was available. The Affymetrix data for TACI expression perfectly matched the real time RT-PCR and previous RT-PCR data 21 and were consistent with the HMCL ability to bind BAFF-murine CD8.
Indeed TACI had an Affymetrix "absent" call (as decided by the GCOS-software) in these HMCLs that showed a lack of TACI mRNA expression by real time or conventional RT-PCR and a lack of binding of BAFF-murine CD8. TACI had an Affymetrix "present" call in the TACI RT-PCR + HMCLs which also bound BAFF-murine CD8 ( Table 1 ). The BCMA gene had a "present" call in 17/17 HMCLs, as had been assumed after BCMA was found in RT-PCR experiments ( Table 1 ). These data suggest that although BCMA is expressed, the BCMA protein is not functional, possibly due to retention in the Golgi apparatus as shown for plasma cells 31 . This observation holds true for purified primary MMC. MMC (# 1-5) that highly expressed BCMA but weakly TACI according to RT-PCR results, failed to bind BAFF-murine CD8 ( Figure 2 ). In contrast, primary MMC (# 6-10) that highly expressed TACI bound human BAFF-murine CD8 ( Figure 2 ). Thus, TACI gene expression yields a BAFFbinding receptor in HMCLs or primary MMC.
Clinical and genetic data of the TACI low and TACI high patients
Gene expression profiles of the 65 primary myeloma cell samples were determined with Affymetrix microarrays. TACI had a "present" Affymetrix call in all primary MMC investigated, displaying a lognormal distribution. We did not find the clear-cut difference (absent or present Affymetrix call) for primary MMC which was observed for HMCls. One possible explanation is the presence of MMC subclones with different levels of TACI expressions in the same patient. We looked for differences in the major clinical, biological or genetic markers in patients with a low or high TACI expression in MMC (TACI low or TACI high patients). To find the best way to delimit TACI low and TACI high patients, we considered subgroups defined by 50%, 40%, 25% or 15%, respectively, of the patients with the highest or lowest TACI expression in MMC. The clinical and biological differences observed showed the clearest distinction when the 15%-group was considered. Here, the TACI high group included a higher frequency of patients within stage I MM, with lambda light-chain isotype, with t(4;14) translocations, with hemoglobin > 10 g/dL, and a lower frequency of patients with bone lesions ( Table 2 ). The percentage of patients with MMC harboring a t(4; 14) translocations was 14% in agreement with published data 3, 32 . Most of these differences were kept when considering TACI groups representing 25% and 40% of the patients (distribution of bone lesions, t(4;14) translocations, lambda light chain isotype). However, they were lost when considering TACI subgroups delimited by the median. Whatever method used to define TACI low and TACI high subgroups, no differences in age, 2m, CRP, albumin, LDH levels, IgG subtypes, or chromosome 13 deletion were found ( Table 2 ).
Gene expression signature of microenvironment dependence in TACI high MMC and plasmablastic signature in TACI low MMC with Affymetrix microarrays
In order to investigate if different gene signatures could be identified comparing two groups with different TACI expression, we performed a supervised clustering. We considered the three groups with significant clinical differences (40%, 25% and 15% of the patients). Of 49.000 probesets present on the U133 A+B DNA-microarrays, we found 1612, 2709 and 1805 probesets, respectively, to be differentially expressed between the two groups (P ≤ .01 with Mann Whitney test and ratio of the mean expressions ≥ 1.5 or ≤ 0.67). To get an impression about the number of genes differentially expressed by chance between the groups, we performed 100 permutations with two subgroups comprising 40%, 25% or 15% of the MM patients randomly sorted out of the 65 samples. Only 5% of the genes appeared to be differentially expressed, if the groups were selected by chance. A common set of 548 distinct genes and 111 distinct expressed sequence tags (EST) were differentially expressed between TACI high and TACI low MMC independently of the definition of TACI high and TACI low groups. This list of 659 genes/EST is available on our web site as supplementary Tables A and B. We performed an unsupervised hierarchical clustering using these 659 genes/EST (Figure 3 A) Affymetrix data showed a good correlation (r ≥ .85, P ≤ .01) ( Figure 4 ).
339 of the 659 genes and ESTs mentioned above (52% of the 479 genes/EST overexpressed in TACI high patients and 50% of the 180 genes/EST overexpressed in TACI low patients) could be assigned to 8 functional categories listed in Table 3 using Gene Ontology terms. TACI high MMC expressed a higher percentage of genes coding for intercellular communication signals, cytoskeleton-associated proteins and signal transduction (Table 3) . Conversely, TACI low MMC overexpressed genes coding for proteins involved in cell cycle and nuclear functions (Table 3) .
TACI high MMC have a BMPC signature and TACI low a plasmablastic signature
We investigated the association of plasmablasts and normal BMPCs with MMC in the TACI high and TACI low groups. Using an unsupervised clustering with the above Taken together, these results suggest that grouping of patients in accordance with "high" and "low" TACI expression delineates a group of patients whose MMC share gene expression characteristics with plasmablasts (TACI low ) and a group in which the gene expression profiling resembles normal mature BM plasma cells (TACI high ).
TACI high MMC overexpress many genes coding for potentially interesting intercellular communication or transduction signals whose biology is discussed below. In contrast, TACI low MMC mainly overexpress cell cycle genes.
Modulation of gene expression profile by addition or deprivation of BAFF and APRIL in MMC
In order to look whether the TACI high and TACI low gene signature could be induced by BAFF/APRIL, we first used the XG-13 HMCL which is stimulated by BAFF and APRIL 21 . After growth factor starvation, addition of BAFF and APRIL for 10 hours induced an increase of 196 genes/EST and a decrease of 348 genes/EST (P ≤ .01 and ratio ≥ 1.5 or ≤ 0.67). However, only 19 genes were common with the TACI-related gene signature (supplementary data in Table E ). We then 26 decided to investigate the effect of BAFF/APRIL deprivation using a whole BM culture system in which BAFF and APRIL were blocked by TACI-Fc inhibitor for 10 hours. Subsequently, MMC were purified for gene expression profiling with Affymetrix U133 2.0 plus microarrays. 188 genes and ESTs were down regulated in BAFF/APRIL deprived MMC (treated with TACI-Fc) and 259 were upregulated (P ≤ .01 and ratio ≥ 1.5 or ≤ 0.67). However, only some of these genes were common with the TACI high of TACI low gene signature.
This list is available as supplementary data in Table F .
Discussion
Two recent studies have shown that BAFF and APRIL are growth factors for human MMC and that serum levels of BAFF and APRIL are increased in these patients 21, 22 .
Using real time PCR, we show that BAFF and APRIL genes are poorly expressed by Primary MMC can survive in contact with BMSCs 35 or osteoclasts 36 . In addition, fetal bone is critical to grow MMC in SCID mice 37, 38 . As these bone cells cannot be harvested by BM aspiration, they are usually produced in vitro. We show here that cultured osteoclasts display a huge APRIL expression, about 80-fold higher than those found in the MM BM environment or in dendritic cells. The BAFF expression was in the same order of magnitude in both cases. Using ELISA, we confirmed that osteoclasts produced very large amounts of APRIL. Thus APRIL could likely play an important role in the MMC growth stimulation by osteoclasts 36 . BM stromal cells produced only a low amount of BAFF and no APRIL.
Purified MMC also express BAFF or APRIL but in the median about 100 fold weaker than the BM environment. This BAFF or APRIL expression pattern and distribution resembles the one of IL-6. A current consensus is that IL-6 is a paracrine growth factor in multiple myeloma and that some MMC may produce autocrine IL-6 and uses it to escape from their dependency on the tumor environment. 39, 40 . 39, 40 In particular, several HMCLs use IL-6 as an autocrine growth factor 41, 42 . Similarly, we have previously found that two HMCLs -L363 and RPMI 8226 -use BAFF or APRIL as autocrine growth factors, while we found here that BAFF and APRIL are mainly paracrine growth factors if assessing primary MM cells. The autocrine production may have contributed to the escape of these MMC from the tumor environment.
Given that BAFF and APRIL are paracrine growth factors, our aim was to look for a difference in the GEP of patients' MMC expressing a high or a low level of BAFF and APRIL receptors. An important point is that TACI expression (assayed with Affymetrix microarrays or RT-PCR) is a good indicator for the presence of a receptor, able to bind BAFF. There are three receptors for BAFF and APRIL, BCMA, BAFF-R and TACI. Probesets for BCMA and TACI were available on the Affymetrix U133 A+B chips, unlike BAFF-R. We could not identify an EST with BAFF-R sequence homology in any Affymetrix probesets. BCMA was probably not functional in MMC and TACI expression was a good indicator of a functional BAFF receptor. Indeed only the 6 out of the 17 HMCLs with a "present" call for TACI expression with Affymetrix microarrays were able to bind a BAFF-murine fusion protein, independent of BCMA expression. BCMA was already shown to be not functional in several cell types, in particular in human plasma cells and the U266 myeloma cell line due to retention in golgi apparatus 31 . However, it is not likely the case for murine plasma cells since BCMA -/mice have normal B cell function but fail to develop mature plasma cells 43 .
When grouping the patients in accordance with the TACI-expression levels as described above, the MMC in the TACI high group show a signature resembling mature BMPCs with an emphasis on the expression of genes with products functioning in intercellular communication and signal transduction. In contrast, the TACI low MMC showed a signature sharing similarities with plasmablasts, especially as regards to the expression of cell cycle genes. The consistency of this signature was validated on an independent group of 40 MMC using Affymetrix U133 2.0 plus microarrays. We looked for the possibility that this gene signature could be due in part to signal transduction induced by TACI activation. We used first the XG-13 HMCL whose growth is stimulated by BAFF or APRIL 21 . We also used primary MMC from a newlydiagnosed patient. In this case, as primary MMC rapidly apoptosed as soon as they are purified 26 , we looked for the effect of BAFF/APRIL deprivation on the gene expression profile of MMC cultured together with their BM environment. In the two cases investigated, a large number of genes were up-or downregulated but only a few genes belonged to the TACI signature.
This indicated that this gene signature is not linked to TACI stimulation but to the degree of dependency of myeloma cell growth on the interaction with the BM environment. As BAFF or APRIL are mainly produced by the BM environment and are potent growth factors for normal and malignant plasma cells, it seems logical that MMC that depend more on BAFF/APRIL for their growth, overexpress TACI and molecules involved in the interaction with their environment.
Of interest, clinical and genetic differences were found between patients with TACI low or TACI high MMC. TACI low patients had a plasmablast signature, an increase in the percentage of stage III MM, a decrease in hemoglobin level, an increase in the percentage of bone lesions. It is of note that clinical parameters and risk factors (2m, CRP, LDH) were not different between TACI groups suggesting that TACI might be an independent prognostic factor, which has to be evaluated in further studies. No significant difference in event-free and overall survivals were found between TACI low and TACI high patients. This is understandable because the median follow-up of this series of patients was short at the time of the study (18 months It was not in the scope of our work to comment on all the genes differentially expressed between TACI low and TACI high MMC. Therefore, in figure 6, we have selected for genes that appeared to us the most promising for myeloma biology understanding. First, we found an increased proportion of MMC secreting lambda light chain in TACI high MMC. Given that immunoglobulin light chain rearrangement occurs in pre-B cells, we have no explanation for this observation. Focusing on growth factor related molecules, we found that MMC in the TACI high group overexpress two neurotrophic tyrosine kinase receptors, NTRK3 which binds neurotrophin 3 and NTRK4. They also overexpress Platelet derived growth factor, CCR6, TNF, interleukin-22 receptor, two ephrins (B4 and B6) and the somatostatin receptor 2 (SSTR2). The IL-22 receptor complex consists of IL-10R and IL-22R 44 .
The IL-10R serves as a common receptor chain for both IL-10 and IL-22. As we previously demonstrated IL-10 to be a growth factor for human MMC 45 , the role of IL-22 in multiple myeloma biology needs to be investigated. The somatostatin receptor family comprises several members and SSTR2 is expressed in different cancers 46, 47 .
Of interest, the somatostatin analog octeotride binds SSRT2 and has been shown to induce apoptosis in MMC 48 . MMC in the TACI high group overexpress the carcinoembryonic antigen-related cell adhesion molecule (CEACAM)1, CEACAM5
and CEACAM6 adhesion molecules. CEACAM1 is necessary for VEGF activity 49 .
Given the likely role of VEGF in multiple myeloma, a role of CEACAM1 in MM demands further investigation. Furthermore, we found an overexpression of two ephrin receptors: EphB4 and EphB6. Ephrin receptors are overexpressed in various tumor types, suggesting that they play a role in cancer progression 50 . Recently, a study demonstrated that EphB4 acts pro-angiogenic in breast cancer 51 . It proposes that the interplay between the EphB4 ectodomain on tumor cells and the ephrin-B2 in the vasculature promotes blood vessel formation and remodeling. TACI high MMC overexpress the chemokine CXCL1. This is of interest because CXCL1 was recently found to bind soluble syndecan-1 52 , a proteoglycan that is a hallmark of plasma cell differentiation. Actually, MMP7 deficient mice have a major defect in neutrophil attraction due to a defect in cleavage of syndecan-1 by MMP7, of binding of CXCL-1 to syndecan-1 and thus of a chemoattracting role of CXCL-1 52 . MMC produce soluble syndecan-1, the serum level of which is increased in patients with MM 53 .
MMP7 is expressed in all myeloma cell samples investigated by Affymetrix microarrays. CXCL1 produced by MMC in the TACI high group could play an important role in the biology of MMC by recruiting cells of the microenvironment, in particular PMN that largely express BAFF.
Regarding adhesion molecules, MMC in the TACI high group overexpress several of theses, in particular integrin alpha 2B, also overexpressed in BMPCs compared to plasmablasts 54 .
Regarding the transduction elements that may be associated with TACI activation, we found an overexpression of mitogen-activated kinase kinase 3 (MKK3), mitogenactivated protein kinase (ERK2), mitogen-activated protein kinase 10 (JNK3), mitogen-activated protein kinase 14 (P38 MAP Kinase), and mitogen-activated protein kinase 8-interacting protein 2 (JIP2) in MMC belonging to the TACI high group.
The substrate of MKK3 is P38 MAP kinase, which is known to be induced by BAFF/APRIL in various cells 55 . JIP2 forms complexes with MAP kinases, in particular with MKK3 and P38 56, 57 . The overexpression of ERK2 in MMC of the TACI high group is in good agreement with our previous results demonstrating that the MAPK pathway is activated, in MMC, by BAFF and APRIL. P38 kinase is also activated in MMC and an inhibitor of P38 induces apoptosis in MMC 58 . BAFF/APRIL trigger PI-3 kinase in MMC 21 , and in good agreement, the P85 subunit of PI-3K is overexpressed in TACI high MMC. PIK3CD (P110 delta polypeptide) is also overexpressed in TACI high MMC. P110 delta is expressed at high levels in lymphocytes of lymphoid tissues and play a role in phosphatidylinositol 3-kinasemediated signaling in the immune system 59 Previously, we demonstrated that BAFF and APRIL induce the upregulation of the anti-apoptotic protein Bcl-2 21 . Confirming these results, we show here that TACI high patients overexpress Bcl-2.
MMC from patients belonging to the TACI low group overexpress genes coding for proteins implicated in cell-cycle and in nuclear functions. These cells overexpress genes coding for protein involved in G1/S transition and mitosis and contributing to plasmablastic signature. Among them, we validated two genes: thymidilate synthetase (TYMS) and cell cycle controller CDC2. 61 Their overexpression is associated with chemotherapy resistance in cancer 62, 63 and these two genes are also differentially expressed between patients with or without chromosomal abnormalities 33 . 64 MMC in the TACI low group overexpress two genes coding for proteasome subunits and could also be an indicator of increased sensitivity to proteasome inhibitors 65 . MMC from patients belonging to the TACI low group overexpress c-met, the receptor of HGF. HGF is a myeloma growth factor 66, 67 . 68 These results suggest that c-met could be a therapeutic target in TACI low MMC.
In conclusion, TACI is overexpressed in patients whose MMC have a gene signature indicative of a dependence on the tumor environment. This fits well with the production of the TACI ligands, BAFF and APRIL, by the tumor environment. TACI low MMC overexpress in turn cell cycle genes indicative of a plamablastic signature.
Taken together, our findings foster a clinical use of inhibitors interfering with the BAFF/APRIL -TACI interaction like the TACI-Fc fusion protein, and at the same time suggest to use gene expression profiling to identify the group of patients which might benefit most from this kind of treatment. The 659 genes that statistically (P ≤ .01) distinguished (ratio ≥ 1.5 or ≤ 0.67) TACI high patients and TACI low patients are presented graphically using hierarchical clustering.
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The color of each cell in the tabular image represents the expression level of each gene (red, expression higher than the mean; green, expression lower than the mean; increasing color intensity represents a higher magnitude of deviation from the mean). A. Initial set of 65 patients.
B. Validation set of 40 patients. 
